RT Journal Article
SR Electronic
T1 COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.06.20076687
DO 10.1101/2020.05.06.20076687
A1 Draghici, Sorin
A1 Nguyen, Tuan-Minh
A1 Sonna, Larry A.
A1 Ziraldo, Cordelia
A1 Vanciu, Radu
A1 Fadel, Raef
A1 Morrison, Austin
A1 Ramesh, Mayur
A1 Mor, Gil
YR 2020
UL http://medrxiv.org/content/early/2020/05/19/2020.05.06.20076687.abstract
AB Background Current management efforts of COVID-19 include: early diagnosis, use of antivirals and immune modulation. After the initial viral phase of the illness, identification of the patients developing cytokine storm syndrome is critical. Treatment of this hyper-inflammation in these patients using existing, approved therapies with proven safety profiles could address the immediate need to reduce the rising mortality.Methods Using data from an A549 cell line, primary human bronchial epithelial (NBHE), as well as from COVID-19-infected lung, we compare the changes in the gene expression, pathways and mechanisms between SARS-CoV2, influenza A, and respiratory syncytial virus.Results We identified FDA-approved drugs that could be repurposed to help COVID-19 patients with severe symptoms related to hyper-inflammation. An important finding is that drugs in the same class will not achieve similar effects. For instance methylprednisolone and prednisolone were predicted to be effective in reverting many of the changes triggered by COVID-19, while other closely related steroids, such as prednisone or dexamethasone, were not. An independent clinical study evaluated 213 subjects, 81 (38%) and 132 (62%) in pre-and post-methylprednisolone groups, respectively. The composite end point was composed of escalation to intensive care units, need for mechanical ventilation, and death. The composite endpoint occurred at a significantly lower rate in post-methylprednisolone group compared to pre-methylprednisolone group (34.9% vs. 54.3%, p=0.005).Conclusion Clinical results confirmed the efficacy of the in silico prediction that indicated methylprednisolone could improve outcomes in severe COVID-19. These findings are important for any future pandemic regardless of the virus.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04374071Funding StatementAdvaitaBio is supported by a National Science Foundation grant 1853207: SBIR Phase II:A multi-omics data integration approach for precision medicine and improved clinical trial success. The clinical study undertook at HFSH did not use any external funding.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe gene expression data analyzed here are available in GEO as data set GSE147507. All clinical data will be publicly available one year after the peer-review publication date.